Korea Advanced Institute of Science and Technology
发明人:
申请号：
EP19187282.9
公开号：
EP3597739A1
申请日:
2019.07.19
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention relates to a method for reverting cancer cells to normal cells using a specific molecular target. The present inventors have newly identified that SETDB1 according to the present disclosure is a key protein regulating cancer growth and differentiation ability, and that the SETCD1 inhibition may allow cancer cell malignancy to be markedly reduced and may promote differentiation of the cancer cell into the same state as normal cells. Thus, the SETDB1 not only provides a novel molecular target for the prevention or treatment of cancer, but also may be useful for the development of anti-cancer drugs.
